Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 2, 2009, Pages 175-185

  Varela, E ^b   Antolin M ^a,b   Guarner, F ^b   Verges, R ^b   Giralt, J ^b   Malagelada, J R ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; DNA;

ABDOMINAL CRAMP; ACUTE DIARRHEA; ACUTE DISEASE; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COMMON TOXICITY CRITERIA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS; PELVIS RADIOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIATION HAZARD; RECTUM CANCER; RECTUM HEMORRHAGE; STATISTICAL ANALYSIS; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PELVIS; RADIATION INJURIES; UTERINE CERVICAL NEOPLASMS;

EID: 67649858417     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04019.x     Document Type: Article

References (32)

1. Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1111-7.
2. Kozelsky T, Meyers GE, Sloan JA, et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhoea in patients receiving pelvic radiation therapy. J Clin Oncol 2003; 21: 1669-74.
3. Valls A, Pestchen I, Prats C, et al. Multicentric double blind clinical trial comparing sucralfate vs placebo for the prevention of diarrhoea secondary to pelvic irradiation. Med Clin 1999; 113: 6814.
4. Andreyev J. Gastointestinal complications of pelvic radiotherapy: are they of any importance? Gut 2005; 54: 1051-4.
5. Valdagni R, Rancanti T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 2008; 71: 106573.
6. Andreyev HJN. Gastrointestinal problems following pelvic radiotherapy. Clin Oncol 2007; 19: 790-9.
7. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformai radiotherapy and intensity-modulated radiotherapy for lacalized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1124-9.
8. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
9. Larsen A, Hovdenak N, Karlsdottir Á, et al. Faecal calprotectin and lactoferrin as a markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 2004; 30: 1113-8.
10. Larsen A, Bjorge B, Klementsen B, et al. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncol 2007; 46: 639-50.
11. Wedlake L, McGough C, Hackett C, et al. Can biological markers act as non-invasive, sensitive indicators of radiationinduced effects in the gastrointestinal mucosa? Aliment Pharmacol Ther 2008; 27: 980-7.
12. Hille A, Schmidt-Giese E, Hermann RM, et al. A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation prostitis in prostate cancer treatment. Scand J Gastroenterol 2008; 43: 52-8.
13. Christiansen H, Saile B, Hermann RM, et al. Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in haemoglobin levels in primary radiotherapy for prostate cancer. J Cancer Res Clin Oncol 2007; 133: 297-304.
14. Lipkin M, Bell B, Sherlock P. Cell proliferation kinetics in the gastrointestinal tract of man. I. Cell renewal in colon and rectum. J Clin Invest 1963; 42: 767-76.
15. Shorter RG, Moertel CG, Titus JL, et al. Cell kinetics in the jejunum and rectum in man. Am J Dig Dis 1964; 9: 760-3.
16. Casellas F, Antolín M, Varela E, et al. Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis. Clin Gastroenterol Hepatol 2004; 2: 683-9.
17. Klaassen CH, Jeunink MA, Prinsen CF, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003; 49: 1185-7.
18. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 113-23.
19. Kristinsson J, Roseth A, Fagerhol MK, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998; 41: 316-21.
20. Tibbie J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402-8.
21. Tibbie J, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 362-6.
22. Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAIDinduced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-8.
23. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-ill-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-4.
24. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-7.
25. Tibbie JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 1522.
26. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 367-8.
27. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003; 49: 8617.
28. Tibbie J, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60.
29. Goy JA, Eastwood MA, Mitchell WD, et al. Fecal characteristics contrasted in the irritable bowel syndrome and diverticular disease. Am J Clin Nutr 1976; 29: 1480-4.
30. Wang C-J, Wang Leung S, Chen H-C. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect. Int J Radiat Oncol Biol Phys 1998; 40: 85-91.
31. Khalid U, McGough C, Hackett C, et al. A modified inflammatory bowel disease questionnaire and the Vaisey incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTGO grading. Int J Radiat Oncol Biol Phys 2006; 64: 1432-41.
32. Hovdenak N, Karlsdottir A, Sorbye H, et al. Profiles and time course of acute radiation toxicity symptoms during conformai radiotherapy for cancer of the prostate. Acta Oncol 2003; 42: 741-8.